BioNTech To Initiate Phase 1/2 Clinical Trial Of MRNA-based Mpox Vaccine Program BNT166

RTTNews | 428 dni temu

(RTTNews) - BioNTech SE (BNTX) and the Coalition for Epidemic Preparedness Innovations (CEPI) announced Monday a strategic partnership to advance mRNA-based vaccine candidates with the development of BNT166 for the prevention of mpox (formerly monkeypox)

mpox, caused by a member of the Orthopoxvirus viral family, is an infectious disease that can lead to severe, life-threatening complications.

CEPI will provide funding of up to $90 million to support the development of mRNA-based vaccine candidates.

Under the partnership, BioNTech is initiating a Phase 1/2 clinical trial of the mRNA-based mpox vaccine program, BNT166.

The clinical trial (NCT05988203) will evaluate the safety, tolerability, reactogenicity and immunogenicity of two mRNA-based multivalent vaccine candidates for active immunization against mpox.

The Phase 1/2 trial aims to enroll 196 healthy participants with and without prior history of known or suspected smallpox vaccination (vaccinia-naive participants).

The mpox vaccine program BNT166 is part of BioNTech's efforts to develop novel prophylactic vaccines for a range of infectious diseases with a high medical need.

BioNTech is aiming to develop a prophylactic mRNA-based mpox vaccine with a favorable safety profile that can be manufactured at scale.

The BNT166 vaccine candidates encode surface antigens that are expressed in the two infectious forms of the monkeypox virus (MPXV) to efficiently fight virus replication and infectivity.

The strategic partnership between BioNTech and CEPI is aiming to contribute to CEPI's 100 Days Mission, a global goal to accelerate development of well-tolerated and effective vaccines that can be ready for regulatory authorization and manufacturing at scale within 100 days of recognition of a pandemic pathogen.

This mission is spearheaded by CEPI and embraced by the G7, G20, and industry leaders.

The data generated could contribute to the rapid development of mRNA-based vaccines against future outbreaks caused by Orthopoxviruses.

Tagi: BNTX

FDA Approves Updated Pfizer, Moderna Covid Vaccines Against Current Variants

The U.S. Food and Drug Administration approved and granted emergency use authorization or EUA for updated Covid vaccines from Pfizer Inc. and ModernaTX Inc. for use against currently circulating variants. The approval for the updated mRNA COVID-19 vaccines (2024-2025 formula) comes as the Covid cases are surging in the United States.

RTTNews | 88 dni temu

Pfizer, BioNTech Announce Top-line Results In Phase 3 Trial Of MRNA-based Combination Vaccine

Drug giant Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced Friday top-line results from their Phase 3 clinical trial to evaluate the companies' combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age.

RTTNews | 95 dni temu

BioNTech And CEPI Expand Strategic Partnership To Boost African Vaccine Ecosystem

BioNTech SE (BNTX) and the Coalition for Epidemic Preparedness Innovations or CEPI, announced Wednesday they are expanding their strategic partnership to contribute to building a sustainable and resilient end-to-end African vaccine ecosystem.

RTTNews | 174 dni temu

BioNTech Slips To Loss In Q1

Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) reported Monday a net loss of 315.1 million euros or 1.31 euros per share for the first quarter, compared to net profit of 502.2 million euros or 2.05 euros per share in the prior-year quarter.

RTTNews | 197 dni temu

BioNTech Q4 Net Profit Plummets

Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) announced Wednesday a profit for the fourth quarter that plummeted from last year, reflecting sharply lower global delivery of its COVID-19 vaccine. The company also initiated its group revenue guidance for the full-year 2024.

RTTNews | 244 dni temu

FDA Authorizes Changes To Simplify Use Of Moderna, Pfizer Bivalent COVID-19 Vaccines

The U.S. Food and Drug Administration said it has amended the emergency use authorizations or EUAs of COVID-19 bivalent mRNA vaccines of ModernaTX Inc. and Pfizer-BioNTech to simplify the vaccination schedule for most individuals. With the changes, the current bivalent vaccines, for original and omicron BA.4/BA.5 strains, can be used for all doses administered to individuals 6 months of age and...

RTTNews | 580 dni temu

FDA Authorizes Bivalent Pfizer Covid Vaccine As Booster Dose For Select Children Under 5

The U.S. Food and Drug Administration has authorized bivalent Pfizer-BioNTech covid-19 vaccine as booster dose for certain children 6 months through 4 years of age. In a statement, the health regulator said it has amended the emergency use authorization or EUA of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent. According to the agency, children 6 months through 4 years of age who completed ...

RTTNews | 615 dni temu

Pfizer Seeks FDA Approval For Bivalent COVID-19 Vaccine In Kids Under 5

Vaccine partners Pfizer Inc. and BioNTech SE are seeking emergency use authorization or EUA from the U.S. Food and Drug Administration to offer their bivalent COVID-19 vaccine to children 6 months through 4 years of age. If authorized, the vaccine would be part of a primary series for children in this age group.

RTTNews | 714 dni temu

EURUSD	1.05652	GBPUSD	1.26339	AUDUSD	0.64958
USDJPY	154.124	USDCAD	1.40186	USDCHF	0.88332